Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Recent treatment strategy for advanced squamous cell carcinoma of the lung in Japan.

Literature DB >> 30847617

Recent treatment strategy for advanced squamous cell carcinoma of the lung in Japan.

Satoru Senoo¹, Kiichiro Ninomiya¹, Katsuyuki Hotta^2,3, Katsuyuki Kiura⁴.

Abstract

Squamous cell carcinoma of the lung is associated with smoking in its development and comprises about 20-30% of all lung cancers. Its treatment strategy had been limited for the past decades, inevitably resulting in the poor outcome. However in the 2010s, it has dramatically changed mainly with the recent clinical introduction of immune checkpoint inhibitors. In this review, we will introduce various clinical studies involving squamous cell carcinoma of the lung.

Entities: Disease

Keywords: Cytotoxic drug; Immune checkpoint inhibitor; Squamous cell carcinoma of the lung

Mesh：

Substances：

Year: 2019 PMID： 30847617 DOI： 10.1007/s10147-019-01424-y

Source DB: PubMed Journal: Int J Clin Oncol ISSN： 1341-9625 Impact factor: 3.402

49 in total

1. Long-standing debate on cisplatin- versus carboplatin-based chemotherapy in the treatment of advanced non-small cell lung cancer.

Authors: Katsuyuki Hotta; Keitaro Matsuo
Journal: J Thorac Oncol Date: 2007-01 Impact factor: 15.609

2. A phase I/II study of cisplatin and vinorelbine chemotherapy in patients with advanced non-small cell lung cancer.

Authors: K Hotta; I Sekine; T Tamura; M Sawada; H Watanabe; H Kusaba; Y Akiyama; A Inoue; T Shimoyama; H Nokihara; Y Ueda; N Yamamoto; H Kunitoh; Y Ohe; T Kodama; N Saijo
Journal: Jpn J Clin Oncol Date: 2001-12 Impact factor: 3.019

3. Interstitial lung disease in Japanese patients with non-small cell lung cancer receiving gefitinib: an analysis of risk factors and treatment outcomes in Okayama Lung Cancer Study Group.

Authors: Katsuyuki Hotta; Katsuyuki Kiura; Masahiro Tabata; Shingo Harita; Kenichi Gemba; Toshiro Yonei; Akihiro Bessho; Tadashi Maeda; Tomonori Moritaka; Takuo Shibayama; Keisuke Matsuo; Katsuya Kato; Arihiko Kanehiro; Yasushi Tanimoto; Keitaro Matsuo; Hiroshi Ueoka; Mitsune Tanimoto
Journal: Cancer J Date: 2005 Sep-Oct Impact factor: 3.360

4. Addition of platinum compounds to a new agent in patients with advanced non-small-cell lung cancer: a literature based meta-analysis of randomised trials.

Authors: K Hotta; K Matsuo; H Ueoka; K Kiura; M Tabata; M Tanimoto
Journal: Ann Oncol Date: 2004-12 Impact factor: 32.976

5. Meta-analysis of randomized clinical trials comparing Cisplatin to Carboplatin in patients with advanced non-small-cell lung cancer.

Authors: Katsuyuki Hotta; Keitaro Matsuo; Hiroshi Ueoka; Katsuyuki Kiura; Masahiro Tabata; Mitsune Tanimoto
Journal: J Clin Oncol Date: 2004-08-23 Impact factor: 44.544

6. Recent improvement in the survival of patients with advanced nonsmall cell lung cancer enrolled in phase III trials of first-line, systemic chemotherapy.

Authors: Katsuyuki Hotta; Yoshiro Fujiwara; Keitaro Matsuo; Takeshi Suzuki; Katsuyuki Kiura; Masahiro Tabata; Nagio Takigawa; Hiroshi Ueoka; Mitsune Tanimoto
Journal: Cancer Date: 2007-03-01 Impact factor: 6.860

7. Interstitial lung disease in Japanese patients with lung cancer: a cohort and nested case-control study.

Authors: Shoji Kudoh; Harubumi Kato; Yutaka Nishiwaki; Masahiro Fukuoka; Kouichiro Nakata; Yukito Ichinose; Masahiro Tsuboi; Soichiro Yokota; Kazuhiko Nakagawa; Moritaka Suga; Haiyi Jiang; Yohji Itoh; Alison Armour; Claire Watkins; Tim Higenbottam; Fredrik Nyberg
Journal: Am J Respir Crit Care Med Date: 2008-03-12 Impact factor: 21.405

8. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer.

Authors: Giorgio Vittorio Scagliotti; Purvish Parikh; Joachim von Pawel; Bonne Biesma; Johan Vansteenkiste; Christian Manegold; Piotr Serwatowski; Ulrich Gatzemeier; Raghunadharao Digumarti; Mauro Zukin; Jin S Lee; Anders Mellemgaard; Keunchil Park; Shehkar Patil; Janusz Rolski; Tuncay Goksel; Filippo de Marinis; Lorinda Simms; Katherine P Sugarman; David Gandara
Journal: J Clin Oncol Date: 2008-05-27 Impact factor: 44.544

9. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer.

Authors: David H Johnson; Louis Fehrenbacher; William F Novotny; Roy S Herbst; John J Nemunaitis; David M Jablons; Corey J Langer; Russell F DeVore; Jacques Gaudreault; Lisa A Damico; Eric Holmgren; Fairooz Kabbinavar
Journal: J Clin Oncol Date: 2004-06-01 Impact factor: 44.544

10. Clinical significance of epidermal growth factor receptor gene mutations on treatment outcome after first-line cytotoxic chemotherapy in Japanese patients with non-small cell lung cancer.

Authors: Katsuyuki Hotta; Katsuyuki Kiura; Shinichi Toyooka; Nagio Takigawa; Junichi Soh; Yoshiro Fujiwara; Masahiro Tabata; Hiroshi Date; Mitsune Tanimoto
Journal: J Thorac Oncol Date: 2007-07 Impact factor: 15.609

5 in total

Recent treatment strategy for advanced squamous cell carcinoma of the lung in Japan.

1. Long-standing debate on cisplatin- versus carboplatin-based chemotherapy in the treatment of advanced non-small cell lung cancer.

2. A phase I/II study of cisplatin and vinorelbine chemotherapy in patients with advanced non-small cell lung cancer.

3. Interstitial lung disease in Japanese patients with non-small cell lung cancer receiving gefitinib: an analysis of risk factors and treatment outcomes in Okayama Lung Cancer Study Group.

4. Addition of platinum compounds to a new agent in patients with advanced non-small-cell lung cancer: a literature based meta-analysis of randomised trials.

5. Meta-analysis of randomized clinical trials comparing Cisplatin to Carboplatin in patients with advanced non-small-cell lung cancer.

6. Recent improvement in the survival of patients with advanced nonsmall cell lung cancer enrolled in phase III trials of first-line, systemic chemotherapy.

7. Interstitial lung disease in Japanese patients with lung cancer: a cohort and nested case-control study.

8. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer.

9. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer.

10. Clinical significance of epidermal growth factor receptor gene mutations on treatment outcome after first-line cytotoxic chemotherapy in Japanese patients with non-small cell lung cancer.

1. LncRNA PITPNA-AS1/miR-223-3p/PTN axis regulates malignant progression and stemness in lung squamous cell carcinoma.

2. Dioscin facilitates ROS-induced apoptosis via the p38-MAPK/HSP27-mediated pathways in lung squamous cell carcinoma.

3. Identification of Novel Biomarkers Related to Lung Squamous Cell Carcinoma Using Integrated Bioinformatics Analysis.

4. Increased expression of core-fucosylated glycans in human lung squamous cell carcinoma.

5. A 13-gene signature to predict the prognosis and immunotherapy responses of lung squamous cell carcinoma.